MTVA MetaVia Inc.
Company Analysis
Latest News
🔴 MetaVia Inc. is trading 5.5% down today as traders lock in profits after obesity pipeline rally
MetaVia Inc. is trading 5.5% down today at $1.90 as the stock retraces sharp gains driven by recent obesity and cardiometabolic pipeline headlines. • The...
🔴 MetaVia Inc. is trading 6.1% down today as early enthusiasm for obesity pipeline update fades
MetaVia Inc. is trading at $1.84 (6.1% down) as initial gains tied to its obesity and metabolic pipeline update faded during regular trading. • Investors were...
🟢 MetaVia Inc. (MTVA) shares rise 8.7% ahead of conference presentation
MetaVia Inc. is trading at $2.13 (up 8.7%) in pre-market action as investors anticipate a company update on its key drug pipeline later today. • The company...
🔴 MetaVia Inc. is trading 5% down today as dilution fears persist following reverse split approval
MetaVia Inc. is trading 5% down at $1.79 as traders react to last week’s shareholder approval of a reverse stock split and an expanded equity incentive...
🔴 MetaVia Inc. is trading 18.5% down today on dilution fears after reverse split and equity plan approval
MetaVia Inc. is trading 18.5% down at $1.81 after shareholders approved a reverse stock split and an expanded equity incentive plan on June 8. • The approval...
🔴 MetaVia Inc. is trading 20.7% down today after reverse split and equity plan approval
MetaVia Inc. is trading 20.7% down at $1.76 in pre-market, extending a sharp slide after stockholders approved a reverse stock split and an expanded equity...
🔴 MetaVia Inc. is trading 12.6% down today after stockholders approved a reverse stock split and equity plan expansion
MetaVia Inc. is trading at $1.94 (-12.61%) in after-hours trading after stockholders approved a reverse stock split and an equity plan expansion during the...
MetaVia Stockholders Approve Reverse Stock Split and Equity Plan Expansion
At its 2026 Annual Meeting on June 8, 2026, MetaVia Inc. (MTVA) stockholders voted to approve all proposals, including a reverse stock split of the company's...
MetaVia Shareholders Approve Reverse Stock Split of Up to 1-for-22
MetaVia Inc. (MTVA) shareholders approved all five proposals during the June 8, 2026, annual meeting. The board gained authority to execute a reverse stock...
MetaVia Reports Positive Phase 1 Data Showing 9.1% Weight Loss for Obesity Drug DA-1726
MetaVia Inc. announced new late-breaking data from its obesity and metabolic disease portfolio presented at the American Diabetes Association’s (ADA) 2026...
🔴 MetaVia Inc. is trading 17.5% down today as traders unwind momentum from ADA conference rally
MetaVia Inc. is trading 17.5% down at $2.12 today as traders unwind momentum following a sharp pullback from last week’s ADA conference rally. • Investors are...
🔴 MetaVia Inc. is trading 13.2% down today as traders unwind momentum following ADA obesity data
MetaVia Inc. is trading 13.2% down at $2.23 in pre-market action as investors digest detailed data from the company's American Diabetes Association (ADA) 2026...
🔴 MetaVia Inc. is trading 6% down today after clinical data on its obesity drug candidate
MetaVia Inc. is trading approximately 6% down at $2.42 in after-hours trading as investors digest clinical data for its dual GLP-1/glucagon candidate,...
MetaVia Surges on New Obesity and Diabetes Drug Data
MetaVia Inc. (MTVA) shares rose following the presentation of new clinical data at the American Diabetes Association’s (ADA) 2026 Scientific Sessions. The...
🟢 MetaVia Inc. is trading 10.6% up today on ADA 2026 abstract acceptance for obesity pipeline
MetaVia Inc. is trading 10.6% up at $2.71 following news that three late-breaking posters were accepted for presentation at the American Diabetes Association...
MetaVia Surges 34% in a Single Session, but Can a Micro-Cap Biotech With Dilution Risk Sustain This Bounce?
Shares of MetaVia Inc. (MTVA) rocketed 33.9% to $3.28 on June 5, clawing back nearly all of a week-long slide that had dragged the stock from $2.84 to $2.45 —...
🟢 MetaVia Inc. is trading 34% up today on obesity pipeline focus and financing updates
MetaVia Inc. is trading 34% up at $3.28 in pre-market, sharply rebounding from a week-long slide that saw shares close at $2.45 on June 04, 2026. • The move...
🔴 MetaVia Inc. falls 4.1% as investors weigh financing risks ahead of key conference and shareholder vote
MetaVia Inc. is trading 4.1% down at $2.57, continuing a sharp pullback from a late-May rally as investors assess financing and listing risks ahead of key...
🔴 MetaVia Inc. is trading 6.3% down today with no clear company-specific catalyst
MetaVia Inc. is trading at $2.51 (6.3% down) amid continued weakness and a lack of fresh company-specific headlines or filings. • The move follows recent...
🔴 MetaVia Inc. is trading 11.36% down today on continued speculative profit-taking following ADA 2026 momentum
MetaVia Inc. is trading at $2.42 (-11.36%) today following a sharp selloff and continued speculative profit-taking. • The recent weakness is tied to prior...